Evidence map›Paper›PMID 34031489›Full record

ArticleScientific reports2021

CD13 is a critical regulator of cell-cell fusion in osteoclastogenesis.

Mallika Ghosh, Tomislav Kelava, Ivana Vrhovac Madunic, Ivo Kalajzic, Linda H Shapiro

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mallika GhoshCenter for Vascular Biology, University of Connecticut Medical School, Farmington, CT, 06030, USA. mghosh@uchc.edu.
Tomislav KelavaCenter for Regenerative Medicine and Skeletal Development, University of Connecticut Dental School, Farmington, CT, 06030, USA.
Ivana Vrhovac MadunicCenter for Regenerative Medicine and Skeletal Development, University of Connecticut Dental School, Farmington, CT, 06030, USA.
Ivo KalajzicCenter for Regenerative Medicine and Skeletal Development, University of Connecticut Dental School, Farmington, CT, 06030, USA.
Linda H ShapiroCenter for Vascular Biology, University of Connecticut Medical School, Farmington, CT, 06030, USA. lshapiro@uchc.edu.
University of Connecticut · US

Funding

Notch Signaling and Bone Fracture HealingR01AR055607 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI Kurt David Hankenson, IVO Kalajzic · 2011 to 2026
$6.3M
Growth Factor Based on Enhancement of Bone RepairR01AR070813 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI KALAJZIC, IVO · 2017 to 2021
$1.7M
Endocytic Regulation of InflammationR01HL127449 · NHLBI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI SHAPIRO, LINDA H · 2015 to 2018
$1.7M
NIAMS NIH HHS R01 AR055607NIAMS NIH HHS R01 AR070813NIH HHS AR070813NIH HHS R01HL127449
6 · The paper itself

Abstract

The transmembrane aminopeptidase CD13 is highly expressed in cells of the myeloid lineage, regulates dynamin-dependent receptor endocytosis and recycling and is a necessary component of actin cytoskeletal organization. Here, we show that CD13-deficient mice present a low bone density phenotype with increased numbers of osteoclasts per bone surface, but display a normal distribution of osteoclast progenitor populations in the bone marrow and periphery. In addition, the bone formation and mineral apposition rates are similar between genotypes, indicating a defect in osteoclast-specific function in vivo. Lack of CD13 led to exaggerated in vitro osteoclastogenesis as indicated by significantly enhanced fusion of bone marrow-derived multinucleated osteoclasts in the presence of M-CSF and RANKL, resulting in abnormally large cells containing remarkably high numbers of nuclei. Mechanistically, while expression levels of the fusion-regulatory proteins dynamin and DC-STAMP1 must be downregulated for fusion to proceed, these are aberrantly sustained at high levels even in CD13-deficient mature multi-nucleated osteoclasts. Further, the stability of fusion-promoting proteins is maintained in the absence of CD13, implicating CD13 in protein turnover mechanisms. Together, we conclude that CD13 may regulate cell-cell fusion by controlling the expression and localization of key fusion regulatory proteins that are critical for osteoclast fusion.

Indexed as

AnimalsBone DensityBone ResorptionCD13 AntigensCell DifferentiationCell FusionCell LineFemaleGene Expression RegulationGene Knockout TechniquesHumansMaleMiceMyeloid Progenitor CellsOsteoclastsU937 CellsCD13 Antigens

Identifiers

PMID34031489
PMCPMC8144195
OpenAlexW3165459015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.